Pitavastatin and Gemfibrozil Interaction
Drug interaction information between Pitavastatin and Gemfibrozil.
Pitavastatin and Gemfibrozil have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Pitavastatin and Gemfibrozil. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Gemfibrozil can cause muscle problems on its own, and the risk becomes even higher when it is mixed with a statin.
What To Do
You should not take these two medications together.
FDA Label Information
Gemfibrozil Clinical Impact: Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with statins, including pitavastatin tablets. Intervention: Avoid concomitant use of gemfibrozil with pitavastatin tablets.
Pitavastatin Also Interacts With
- Cyclosporine major
- Erythromycin major
- Rifampin major
- Colchicine moderate
- Niacin moderate
Gemfibrozil Also Interacts With
- Ezetimibe major
- Ezetimibe/Simvastatin major
- Repaglinide major
- Simvastatin major
- Atorvastatin moderate
Frequently Asked Questions
Can I take Pitavastatin and Gemfibrozil together?
This is a moderate interaction. You should not take these two medications together.
How serious is the interaction between Pitavastatin and Gemfibrozil?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Pitavastatin and Gemfibrozil interact?
Gemfibrozil can cause muscle problems on its own, and the risk becomes even higher when it is mixed with a statin.
Understanding the Pitavastatin and Gemfibrozil Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Pitavastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class and Gemfibrozil belongs to the Fibrate class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Gemfibrozil can cause muscle problems on its own, and the risk becomes even higher when it is mixed with a statin. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Pitavastatin has 9 total documented interactions on file in this dataset, and Gemfibrozil has 20. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You should not take these two medications together. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Pitavastatin or Gemfibrozil based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.